Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD).
exercise
maximum oxygen uptake
outcome
prognosis
survival
Journal
JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
05
04
2021
revised:
14
05
2021
accepted:
18
05
2021
pubmed:
16
8
2021
medline:
29
10
2021
entrez:
15
8
2021
Statut:
ppublish
Résumé
The purpose of this study was to examine whether peak oxygen uptake (pVO pVO We collected data for pVO Nine centers contributed data from 450 patients. Patients were 53 ± 13 years of age; 78% were male; body mass index was 25 ± 5 kg/m Even after LVAD implantation, pVO
Sections du résumé
OBJECTIVES
The purpose of this study was to examine whether peak oxygen uptake (pVO
BACKGROUND
pVO
METHODS
We collected data for pVO
RESULTS
Nine centers contributed data from 450 patients. Patients were 53 ± 13 years of age; 78% were male; body mass index was 25 ± 5 kg/m
CONCLUSIONS
Even after LVAD implantation, pVO
Identifiants
pubmed: 34391745
pii: S2213-1779(21)00324-3
doi: 10.1016/j.jchf.2021.05.021
pii:
doi:
Substances chimiques
Oxygen
S88TT14065
Banques de données
ClinicalTrials.gov
['NCT04423562']
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
758-767Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL146889
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures Dr Mirza received Danish funding from Skibsreder Per Henriksen, R og hustrus Fond grant 10403/53 and Jascha Fonden grants 6186 and 7724. Dr Gustafsson is supported by research grant NNF20OC006056 from the Novo Nordisk Foundation. Dr Brahmbhatt has received travel support from Abbott, Biotronik; and has received honoraria, travel support, and research funding from Boston Scientific (all outside the submitted work). Dr Hsu has received U.S. National Institutes of Health funding (grant K23-HL146889) (all outside the submitted work). Dr MacGowan is supported by EU Horizon 2020 and United Kingdom National Institute of Health Research. Dr Jakovljevic is supported by EU Horizon 2020 Research and Innovation Programme under grant agreements 777204 and 952603. Dr Gustafsson has received personal fees from Abbott, Carmat, Pfizer, Novartis, Orion Pharma, Boehringer Ingelheim, Pharmacosmos, Amgen, Bayer, and AstraZeneca; and is a consultant for Abbott, Carmat, Pfizer, Novartis, Orion Pharma, Boehringer-Ingelheim, Pharmacosmos, Amgen, Bayer and AstraZeneca (all outside the submitted work). Dr Russell is a consultant for Medtronic and Abbott (all outside the submitted work). Dr Jorde is a consultant for Abbott (all outside the submitted work). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.